BullishWhales · Analysts · Analyst Profile
Analyst rating accuracy & track record
Catherine Schulte does not yet have enough resolved 12-month calls to carry a published score. Check back as their ratings mature.
Ratings & price targets
| Stock | Rating | Price target | Rated | 12-mo vs sector | PT hit |
|---|---|---|---|---|---|
 MRVIMaravai Lifesciences Holdings Inc | Buy | $9.00 | Nov 2024 | −46.8% | Miss |
 QGENQiagen NV | Buy | $52.00 | Aug 2024 | +23.9% | Miss |
| MRVIMaravai Lifesciences Holdings Inc | Buy | $10.00 | May 2024 | −75.0% | Hit |
| QGENQiagen NV | Buy | $50.00 | Sep 2023 | −9.3% | Miss |
 RVTYRevvity Inc. | Buy | $165.00 | May 2023 | −18.7% | Miss |
| RVTYRevvity Inc. | Buy | $182.00 | Feb 2023 | −35.5% | Miss |
| RVTYRevvity Inc. | Buy | $202.00 | Aug 2022 | −21.4% | Miss |
| RVTYRevvity Inc. | Buy | $82.00 | May 2018 | +19.2% | Hit |
| RVTYRevvity Inc. | Buy | $78.00 | Nov 2017 | +5.7% | Hit |
Go to
Browse the full analyst leaderboardHow analyst accuracy is scored
Every score, Win %, PT Hit % and rank is an estimate Bullish Whales calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.